"Jan. 1, 2013 -- Antidepressant use during pregnancy, long debated for its safety, is linked with a higher overall risk of stillbirth and newborn death. Now, a new study shows that risk may not be warranted.
"After taking maternal char"...
The lethal dose of Marplan (isocarboxazid) in humans is not known. There has been one report of a fatality in a patient who ingested 400 mg of Marplan (isocarboxazid) together with an unspecified amount of another drug. Symptoms: Major overdosage may be evidenced by tachycardia, hypotension, coma, convulsions, respiratory depression, sluggish reflexes, pyrexia, and diaphoresis; these signs may persist for 8 to 14 days. Treatment: General supportive measures should be used, along with immediate gastric lavage or emetics. If the latter are given, the danger of aspiration must be borne in mind. An adequate airway should be maintained, with supplemental oxygen if necessary. The mechanism by which amine-oxidase inhibitors produce hypotension is not fully understood, but there is evidence that these agents block the vascular bed response. Thus it is suggested that plasma may be of value in the management of this hypotension. Administration of pressor amines such as Levophed® (levarterenol bitartrate) may be of limited value (note that their effects may be potentiated by Marplan (isocarboxazid) ). Continue treatment for several days until homeostasis is restored. Liver function studies are recommended during the 4 to 6 weeks after recovery, as well as the time of overdosage.
In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center on the treatment of any overdose.
Marplan (isocarboxazid) should not be administered in combination with any of the following: MAO inhibitors or dibenzazepine derivatives; sympathomimetics (including amphetamines); some central nervous system depressants (including narcotics and alcohol); antihypertensive, diuretic, antihistaminic, sedative or anesthetic drugs, buproprion HCL, buspirone HCL, dextromethorphan, cheese or other foods with a high tyramine content; or excessive quantities of caffeine.
Marplan (isocarboxazid) should not be administered to any patient with a confirmed or suspected cerebrovascular defect or to any patient with cardiovascular disease, hypertension, or history of headache.
Contraindicated Patient Populations
Marplan (isocarboxazid) should not be used in patients with known hypersensitivity to isocarboxazid.
Marplan (isocarboxazid) should not be administered to any patient with a confirmed or suspected cerebrovascular defect or to any patient with cardiovascular disease or hypertension.
Marplan (isocarboxazid) should not be used in the presence of pheochromocytoma, as such tumors secrete pressor substances whose metabolism may be inhibited by Marplan (isocarboxazid) .
Marplan (isocarboxazid) should not be used in patients with a history of liver disease, or in those with abnormal liver function tests.
Marplan (isocarboxazid) should not be used in patients with severe impairment of renal function.
Contraindicated MAOI-Other Drug Combinations
Other MAOI Inhibitors or With Dibenzazepine-Related Entities
Marplan (isocarboxazid) should not be administered together with, or in close proximity to, other MAO inhibitors or dibenzazepine-related entities. Hypertensive crises, severe convulsive seizures, coma, or circulatory collapse may occur in patients receiving such combinations. In patients being transferred to Marplan (isocarboxazid) from another MAO inhibitor or from a dibenzazepine-related entity, a medication-free interval of at least 1 week should be allowed, after which Marplan (isocarboxazid) therapy should be started using half the normal starting dosage for at least the first week of therapy. Similarly, at least 1 week should elapse between the discontinuation of Marplan (isocarboxazid) and initiation of another MAO inhibitor or dibenzazepine-related entity, or the readministration of Marplan (isocarboxazid) . The following list includes some other MAO inhibitors, dibenzazepine-related entities, and tricyclic antidepressants.
|Generic Name||Trademark (Manufacturer)|
|Other MAO Inhibitors|
|Furazolidone||Furoxone® (Roberts Laboratories)|
|Pargyline HCL||Eutonyl® (Abbott Laboratories)|
|Pargyline HCL and methyclothiazide||Eutron® (Abbott Laboratories)|
|Phenelzine sulfate||Nardil® (Parke-Davis)|
|Procarbazine||Matulane® (Roche Laboratories)|
|Tranylcypromine sulfate||Parnate® (SmithKline Beecham Pharmaceuticals)|
|Dibenzazepine-Related and Other Tricyclics|
|Amitriptyline HCL||Elavil® (Zeneca)|
|Endep® (Roche Products)|
|Perphenazine and amitriptyline HCL||Etrafon® (Schering)|
|Triavil® (Merck Sharp & Dohme)|
|Clomipramine hydrochloride||Anafranil® (Novartis)|
|Desipramine HCL||Norpramin® (Hoechst Marion Roussel)|
|Pertofrane® (Rhone-Poulenc Rorer Pharmaceuticals)|
|Imipramine HCL||Janimine® (Abbott Laboratories)|
|Nortriptyline HCL||Aventyl® (Eli Lilly & Co.)|
|Protripyline HCL||Vivactil® (Merck Sharp & Dohme)|
|Doxepin HCL||Adapin® (Fisons)|
|Cyclobenzaprine HCL||Flexeril® (Merck Sharp & Dohme)|
|Maprotiline HCL||Ludiomil® (Novartis)|
|Trimipramine maleate||Surmontil® (Wyeth-Ayerst Laboratories)|
The concurrent administration of a MAO inhibitor and buproprion hydrochloride (Wellbutrin®, and Zyban®, Glaxo Wellcome) is contraindicated. At least 14 days should elapse between discontinuation of an MAO inhibitor and initiation of treatment with buproprion hydrochloride.
Selective Serotonin Reuptake Inhibitors (SSRIs)
Marplan (isocarboxazid) should not be administered in combination with any SSRI. There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation and confusion progressing to delirium and coma) in patients receiving fluoxetine (Prozac®, Lilly) in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on a MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Fluoxetine and other SSRIs should therefore not be used in combination with Marplan (isocarboxazid) , or within 14 days of discontinuing therapy with Marplan (isocarboxazid) . As fluoxetine and its major metabolite have very long elimination half-lives, at least 5 weeks should be allowed after stopping fluoxetine before starting Marplan (isocarboxazid) . At least 2 weeks should be allowed after stopping sertraline (Zoloft®, Pfizer) or paroxetine (Paxil®, SmithKline Beecham Pharmaceuticals) before starting Marplan (isocarboxazid) . In addition, there should be an interval of least 10 days between discontinuation of Marplan (isocarboxazid) and initiation or fluoxetine or other SSRIs.
Marplan (isocarboxazid) should not be used in combination with buspirone HCL (Buspar®, Bristol Myers Squibb); several cases of elevated blood pressure have been reported in patients taking MAO inhibitors who were then given buspirone HCL. At least 10 days should elapse between the discontinuation of Marplan (isocarboxazid) and the institution of buspirone HCL. Serious reactions may also occur when MAO inhibitors are given with serotoninergic drugs (e.g., dexfenfluramine, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, venlafaxine).
Marplan (isocarboxazid) should not be administered in combination with sympathomimetics, including amphetamines, or with over-the-counter drugs such as cold, hay fever, or weight-reducing preparations that contain vasoconstrictors.
During Marplan (isocarboxazid) therapy, it appears that some patients are particularly vulnerable to the effects of sympathomimetics when the activity of metabolizing enzymes is inhibited. Use of sympathomimetics and compounds such as guanethidine, methyldopa, methylphenidate, reserpine, epinephrine, norepinephrine, phenylalanine, dopamine, levodopa, tyrosine, and tryptophan with Marplan (isocarboxazid) may precipitate hypertension, headache, and related symptoms. The combination of MAO inhibitors and tryptophan has been reported to cause behavioral and neurologic symptoms, including disorientation, confusion, amnesia, delirium, agitation, hypomanic signs, ataxia, myoclonus, hyperreflexia, shivering, ocular oscillations, and Babinski signs.
Meperidine should not be used concomitantly with MAO inhibitors or within 2 or 3 weeks following MAO therapy. Serious reactions have been precipitated with concomitant use, including coma, severe hypertension or hypotension, severe respiratory depression, convulsions, malignant hyperpyrexia, excitation, peripheral vascular collapse, and death. It is thought that these reactions may be mediated by accumulation of 5-HT (serotonin) consequent to MAO inhibition.
Marplan (isocarboxazid) should not be used in combination with dextromethorphan. The combination of MAO inhibitors and dextromethorphan has been reported to cause brief episodes of psychosis or bizarre behavior.
Cheese or Other Foods With a High Tyramine Content
Hypertensive crises have sometimes occurred during Marplan (isocarboxazid) therapy after ingestion of foods with a high tyramine content. In general, patients should avoid protein foods in which aging or protein breakdown is used to increase flavor. In particular, patients should be instructed not to take foods such as cheese (particularly strong or aged varieties), sour cream, Chianti wine, sherry, beer (including non-alcoholic beer), liqueurs, pickled herring, anchovies, caviar, liver, canned figs, raisins, bananas or avocados (particularly if overripe), chocolate, soy sauce, sauerkraut, the pods of broad beans (fava beans), yeast extracts, yogurt, meat extracts, meat prepared with tenderizers, or dry sausage.
Patients taking Marplan (isocarboxazid) should not undergo elective surgery requiring general anesthesia. Also, they should not be given cocaine or local anesthesia containing sympathomimetic vasoconstrictors. The possible combined hypotensive effects of Marplan (isocarboxazid) and spinal anesthesia should be kept in mind. Marplan (isocarboxazid) should be discontinued at least 10 days before elective surgery.
Marplan (isocarboxazid) should not be used in combination with some central nervous system depressants, such as narcotics, barbiturates, or alcohol.
Marplan (isocarboxazid) should not be used in combination with antihypertensive agents, including thiazide diuretics. A marked potentiating effect on these drugs has been reported, resulting in hypotension.
Excessive use of caffeine in any form should be avoided in patients receiving Marplan (isocarboxazid) .
Last reviewed on RxList: 9/14/2007
This monograph has been modified to include the generic and brand name in many instances.
Additional Marplan Information
Marplan - User Reviews
Marplan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on therapy and treatment.